Rohit Joshi

Research Interests

Cancer Biology and Clinical Oncology Cancer Diagnosis Cancer Therapy Oncology and Carcinogenesis Tumour Immunology

Aspr Rohit Joshi

School of Medicine

College of Health

A/Prof Rohit Joshi is a Medical Oncology Consultant working with GenesisCare at Calvary and St Andrew's Hospitals. His public Staff Specialist appointment is at the Lyell McEwin Hospital.Rohit completed his undergraduate training at the Christian Medical College in India, after which he trained in Medical Oncology at the Royal Adelaide Hospital.Rohit is a Fellow of the Royal Australasian College of Physicians (FRACP), Fellow of the American College of Physicians (FACP), Fellow of the Royal College of Physicians (FRCP) and is certified by the European Society of Medical Oncology (ESMO).​Rohit is a Director at Cancer Research SA (CRSA).

Date Position Institution name
2023 - ongoing Associate Professor University of Adelaide
2020 - ongoing Director Cancer Research SA
2018 - 2022 Director, Cancer Research Adelaide Oncology and Haematology
2014 - ongoing Consultant, Medical Oncology GenesisCare
2013 - 2017 Director, Cancer Research and Clinical Trials SA Health - Lyell McEwin Hospital
2013 - ongoing Consultant SA Health - Lyell McEwin Hospital
2010 - 2023 Clinical Lecturer University of Adelaide
2008 - 2010 Assistant Professor Christian Medical College

Language Competency
English Can read, write, speak, understand spoken and peer review
Hindi Can read, write, speak and understand spoken
Panjabi; Punjabi Can read, write, speak and understand spoken

Date Institution name Country Title
2020 Royal College of Physicians United Kingdom FRCP
2015 American College of Physicians USA FACP
2013 Royal Adelaide and Lyell McEwin Hospitals Australia FRACP
1999 - 2002 Christian Medical College India MD
1991 - 1996 Christian Medical College India MBBS

Date Title Institution name Country
2012 European Certified Medical Oncologist (ECMO) European Society of Medical Oncology Switzerland

Year Citation
2026 Lim, A. H., Nitchingham, D., Bednarz, J., Bills, M., Lanka, L., Allen, B., . . . Nguyen, N. Q. (2026). Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity score–weighted landmark analysis. Gastrointestinal Endoscopy, 103(1), 126-135.e5.
DOI Scopus7 WoS4 Europe PMC4
2026 Cross, C. B., Bowen, J. M., Leifert, W. R., Beale, D. J., Francois, M., Joshi, R., . . . Wardill, H. R. (2026). Pre-treatment gut microbiome and salivary metabolome signatures associate with chemotherapy-induced cognitive decline in women with breast cancer: A prospective pilot study. Cancer Letters, 640, 218234-1-218234-5.
DOI Scopus1 WoS1
2026 Joshi, S., Nath, J., Bagri, J., Kumari, K., Roy, A., Yadav, S. K., . . . Joshi, R. (2026). High-Efficiency Regeneration and Transformation System in <i>Nardostachys jatamansi</i> for Functional Genomics and Bioactive Compounds Enrichment. PLANT CELL AND ENVIRONMENT, 49(2), 840-857.
DOI WoS1
2025 Gusain, S., Kumar, R., & Joshi, R. (2025). Abscisic acid-mediated modulation of morpho-physiological traits and transcript accumulation improves drought resilience in <i>Crocus sativus</i> L. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1869(11), 13 pages.
DOI WoS1
2025 Kumari, M., Kumar, P., Saini, V., Joshi, R., Shankar, R., & Kumar, R. (2025). Transcriptional landscape illustrates the diversified adaptation of medicinal plants to multifactorial stress combinations linked with high altitude. PLANTA, 261(5), 25 pages.
DOI WoS5
2025 Joshi, S., & Joshi, R. (2025). Quantifying redox signalling regulatory transcriptional dynamics in<i> Nardostachys</i><i> jatamansi</i> under abiotic stress response. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1869(6), 12 pages.
DOI WoS3
2025 André, T., Elez, E., Lenz, H. J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., . . . Lonardi, S. (2025). Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet, 405(10476), 383-395.
DOI Scopus178 WoS165 Europe PMC88
2025 Kumari, A., Sopory, S. K., & Joshi, R. (2025). Unraveling the intricate tapestry of bamboo transcription factors in abiotic stress signaling and resilience with special reference to moso bamboo family. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1869(2), 13 pages.
DOI WoS5
2025 Bohra, A., Tiwari, A., Pareek, S., Joshi, R., Naik, S. J. S., Kumari, K., . . . Dixit, G. P. (2025). Past and future of cytoplasmic male sterility and heterosis breeding in crop plants. PLANT CELL REPORTS, 44(2), 20 pages.
DOI WoS11
2024 Kumar, A., Rawat, N., Thakur, S., Joshi, R., & Pandey, S. S. (2024). A highly efficient protocol for isolation of protoplast from China, Assam and Cambod types of tea plants [Camellia sinensis (L.) O. Kuntze] (vol 19, 147, 2023). PLANT METHODS, 20(1), 2 pages.
DOI
2024 Lim, A. H. W., Zobel, J., Bills, M., Hsieh, W., Crouch, B., Joshi, R., . . . Nguyen, N. Q. (2024). The impact of combined chemotherapy and intra-tumoural injection of Phosphorus-32 Microparticles on vascularity in locally advanced pancreatic carcinoma. Cancers, 16(19), 1-14.
DOI Scopus8 WoS8 Europe PMC8
2024 Andre, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., . . . Lonardi, S. (2024). Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. New England Journal of Medicine, 391(21), 2014-2026.
DOI Scopus206 WoS200 Europe PMC130
2024 Leighl, N. B., Akamatsu, H., Lim, S. M., Cheng, Y., Minchom, A. R., Marmarelis, M. E., . . . PALOMA-3 Investigators. (2024). Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of Clinical Oncology, 42(30), 3593-3605.
DOI Scopus115 WoS121 Europe PMC106
2023 Murray, J., Bennett, H., Selva Nayagam, S., Joshi, R., Bezak, E., & Perry, R. (2023). Impact of aerobic training on cardiovascular function, fitness, and patient reported outcomes during anthracycline chemotherapy: a case series in women with breast cancer. Integrative Cancer Therapies, 22, 1-13.
DOI Scopus2 WoS1
2023 Lee, C. K., Soon, Y. Y., Jeffree, R. L., Joshi, R., Koh, E. S., Lam, W. S., . . . John, T. (2023). Management paradigm of central nervous system metastases in NSCLC: an Australian perspective. JTO Clinical and Research Reports, 4(9), 1-10.
DOI
2023 Kumar, A., Rawat, N., Thakur, S., Joshi, R., & Pandey, S. S. (2023). A highly efficient protocol for isolation of protoplast from China, Assam and Cambod types of tea plants [<i>Camellia sinensis</i> (L.) O. Kuntze]. PLANT METHODS, 19(1), 15 pages.
DOI WoS8
2023 Gusain, S., Joshi, S., & Joshi, R. (2023). Sensing, signalling, and regulatory mechanism of cold-stress tolerance in plants. PLANT PHYSIOLOGY AND BIOCHEMISTRY, 197, 9 pages.
DOI WoS141
2022 Joshi, S., Chinnusamy, V., & Joshi, R. (2022). Root System Architecture and Omics Approaches for Belowground Abiotic Stress Tolerance in Plants. AGRICULTURE-BASEL, 12(10), 18 pages.
DOI WoS14
2022 Li, M., Reintals, M., D'Onise, K., Farshid, G., Holmes, A., Joshi, R., . . . Roder, D. M. (2022). Investigating the breast cancer screening-treatment-mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data.. European journal of cancer care, 31(1), 12 pages.
DOI Scopus4 WoS3 Europe PMC2
2022 Skrabal, R. X., Gunn, K. M., Suppiah, V., Patterson, P., Boyle, T., Carrington, C., . . . Olver, I. (2022). A smartphone program to support adherence to oral chemotherapy in people with cancer: proof-of-concept trial. Asia-Pacific Journal of Clinical Oncology, 18(5), e378-e387.
DOI Scopus4 WoS4 Europe PMC4
2022 Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., . . . Joshi, R. (2022). Durable responses with intratumoral electroporation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890. CANCER RESEARCH, 82(4), 3 pages.
DOI
2022 Yong, C. H., Gupta, A., & Joshi, R. (2022). CSCO breast cancer management guidelines 2022: Australian perspective. TRANSLATIONAL BREAST CANCER RESEARCH, 3, 36-1-36-4.
DOI
2021 Alawawdeh, A., Krishnan, T., Roy, A., Karapetis, C., Joshi, R., Singhal, N., & Price, T. (2021). Curative therapy for rectal cancer. Expert Review of Anticancer Therapy, 21(2), 193-203.
DOI Scopus8 WoS7 Europe PMC7
2021 Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2021). Female breast cancer treatment and survival in South Australia: Results from linked health data.. Eur J Cancer Care (Engl), 30(5), 1-12.
DOI Scopus4 WoS4 Europe PMC4
2020 Gupta, A., & Joshi, R. (2020). Breast cancer diagnosis and treatment: Asian perspective. TRANSLATIONAL BREAST CANCER RESEARCH, 1, 3 pages.
DOI WoS1
2020 McCaffrey, N., Asser, T., Fazekas, B., Muircroft, W., Agar, M., Clark, K., . . . Currow, D. C. (2020). Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer, 20(1), 9 pages.
DOI Scopus10 WoS10 Europe PMC10
2020 Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2020). Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. BMJ Open, 10(6), e037069.
DOI Scopus8 WoS8 Europe PMC4
2020 Shepherd, A. R. H., Joshi, R., Tan, C. P., Cohen, P., & Brook, N. R. (2020). Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma. ANZ Journal of Surgery, 90(7-8), 1517-1519.
DOI Scopus9 WoS9 Europe PMC8
2019 Tan, J. L., Mugwagwa, A. N., Cieslik, L., & Joshi, R. (2019). Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer. BMJ Case Reports, 12(7), 229963-1-229963-5.
DOI Scopus10 WoS7 Europe PMC8
2019 Roder, D., Karapetis, C. S., Olver, I., Keefe, D., Padbury, R., Moore, J., . . . Price, T. (2019). Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.. BMJ open, 9(9), 1-11.
DOI Scopus34 WoS22 Europe PMC25
2019 Gupta, A., & Joshi, R. (2019). Improving chemotherapy outcome in early breast cancer. Gland Surgery, 8(5), 585-587.
DOI
2019 Parente, P., Chan, B. A., Hughes, B. G. M., Jasas, K., Joshi, R., Kao, S., . . . Stone, E. (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia Pacific Journal of Clinical Oncology, 15(3), 93-100.
DOI Scopus5 WoS4 Europe PMC5
2018 Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. (2018). Phase IB/II study of second-line therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS wild-type metastatic colorectal cancer. Clinical Cancer Research, 24(16), 3838-3844.
DOI Scopus9 WoS7 Europe PMC5
2018 Adelson, P., Fusco, K., Karapetis, C., Wattchow, D., Joshi, R., Price, T., . . . Roder, D. (2018). Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. Journal of Evaluation in Clinical Practice, 24(1), 135-144.
DOI Scopus16 WoS14 Europe PMC15
2017 Currow, D., Watts, G., Johnson, M., McDonald, C., Miners, J., Somogyi, A., . . . Ekström, M. (2017). A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion and Morphine Sulfate (BEAMS) study protocol. BMJ Open, 7(7), e018100-1-e018100-18.
DOI Scopus29 WoS30 Europe PMC27
2017 Roder, D., Farshid, G., Kollias, J., Koczwara, B., Karapetis, C., Adams, J., . . . Price, T. (2017). Female breast cancer management and survival: the experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. Journal of Evaluation in Clinical Practice, 23(6), 1433-1443.
DOI Scopus6 WoS7 Europe PMC5
2017 Aguirre, V. J., Barnett, D., Burdett, N., Joshi, R., & Viana, F. F. (2017). Video-assisted thoracoscopy in the management of intrapleural extravasation of cytotoxic chemotherapy.. Thoracic cancer, 8(4), 363-364.
DOI Scopus4 WoS3 Europe PMC3
2017 Buckley, E., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Roder, D. (2017). Assessing impact of organised breast screening across small residential areas-development and internal validation of a prediction model. European Journal of Cancer Care, 26(4), e12673-1-e12673-8.
DOI
2017 Roder, D., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Beckmann, K. (2017). Breast cancer screening-opportunistic use of registry and linked screening data for local evaluation. Journal of Evaluation in Clinical Practice, 23(3), 508-516.
DOI Scopus4 WoS2 Europe PMC2
2016 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2016). Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly. European Journal of Cancer Care, 25(5), 753-763.
DOI Scopus5 WoS5 Europe PMC4
2016 Beckmann, K. R., Bennett, A., Young, G. P., Cole, S. R., Joshi, R., Adams, J., . . . Roder, D. (2016). Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study. BMC Health Services Research, 16(1), 1-14.
DOI Scopus55 WoS53 Europe PMC43
2015 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Colorectal cancer treatment and survival : the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(6), 2431-2440.
DOI Scopus28 Europe PMC29
2015 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Metastatic colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(14), 5923-5931.
DOI Scopus12 Europe PMC3
2015 Joshi, R., & Joshi, R. (2015). Deconstructing epidemiology. CHRISMED Journal of Health and Research, 2(1), 3.
DOI
2014 Vatandoust, S., Joshi, R., Pitman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2014). A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Supportive Care in Cancer, 22(2), 513-518.
DOI Scopus30 WoS27 Europe PMC20
2013 Butt, S., Vatandoust, S., Kleinig, T., Adams, J., Basu, S., Otto, G., & Joshi, R. (2013). Anti-Ri antibody-associated paraneoplastic brainstem encephalitis successfully treated after treating the underlying malignancy with letrozole. Internal Medicine Journal, 2013(5), 605-606.
DOI Scopus3 WoS3
2013 Mahajan, R., Kuklik, P., Grover, S., Brooks, A., Wong, C., Sanders, P., & Selvanayagam, J. (2013). Cardiovascular magnetic resonance of total and atrial pericardial adipose tissue: A validation study and development of a 3 dimensional pericardial adipose tissue model. Journal of Cardiovascular Magnetic Resonance, 15(1), 1-7.
DOI Scopus47 WoS42 Europe PMC40
2013 Grover, S., Leong, D., Chakrabarty, A., Joerg, L., Kotasek, D., Cheong, K., . . . Selvanayagam, J. (2013). Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers. International Journal of Cardiology, 168(6), 5465-5467.
DOI Scopus103 WoS96 Europe PMC89
2013 Valsalan, R., Joshi, R., Adams, J., & Arstall, M. (2013). Cardiac failure with bevacizumab: An oversight. Asia Pacific Journal of Clinical Oncology, Online(1), 1-2.
DOI
2013 Joshi, R. (2013). Adjuvant colon cancer chemotherapy: is there an Indian standard of care?. South Asian journal of cancer, 2(2), 70-71.
DOI Europe PMC1
2013 Grover, S., DePasquale, C., Srinivasan, G., Leong, D. P., Chakrabarty, A., Cheong, K. A., . . . Selvanayagam, J. (2013). Contemporary breast cancer chemotherapy leads to persistent late right ventricular myocardial dysfunction: a prospective multi-centre study. Journal of Cardiovascular Magnetic Resonance, 15, P164.
DOI
2013 Grover, S., DePasquale, C., Srinivasan, G., Leong, D. P., Chakrabarty, A., Cheong, K. A., . . . Selvanayagam, J. (2013). Early and late left ventricular effects of breast cancer chemotherapy: a prospective multi-centre study using advanced cardiac imaging. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 15(Suppl 1), P142.
DOI Europe PMC1
2012 Vatandoust, S., Joshi, R., Broadbridge, V., Pittman, K. B., Adams, J., Singhal, N., . . . Price, T. J. (2012). Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Journal of Clinical Oncology, 30(15_suppl), e19513.
DOI
2012 Grover, S., DePasquale, C., Leong, D. P., Chakrabarty, A., Cheong, K. A., Kotasek, D., . . . Selvanayagam, J. (2012). Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 14(Suppl 1), P181.
DOI Europe PMC2
2012 Grover, S., De Pasquale, C., Leong, D., Chakrabathy, A., Cheong, K., Kotasek, D., . . . Selvanayagam, J. (2012). Biventricular Ventricular Dysfunction Following Administration of Anthracycline (AC) Chemotherapy In Breast Cancer: A Prospective Multi-Centre Study Using Advanced Cardiac Imaging and Biochemical Markers. Heart, Lung and Circulation, 21, S187.
DOI
2012 Vatandoust, S., Joshi, R., & Price, T. (2012). Guillain-Barré syndrome in colorectal cancer. Asia Pacific Journal of Clinical Oncology, 8(2), 205-208.
DOI Scopus4 WoS3 Europe PMC4
2008 Singhal, N., Hissaria, P., Joshi, R., & Nayagam, S. (2008). Inflammatory myopathy and cancer: Rare association of seminoma testes and polymyositis. Internal Medicine Journal, 38(4), 295-297.
DOI Scopus3 WoS1 Europe PMC2
2008 Joshi, R., Mammen, K., & Pawar, B. (2008). Successful renal transplantation after two separate urinary tract malignancies. Indian Journal of Urology, 24(2), 256-257.
DOI Scopus3 WoS2 Europe PMC2
2007 Joshi, R., Olver, I., Keefe, D., Marafioti, T., & Smith, K. (2007). A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Supportive Care in Cancer, 15(9), 1109-1112.
DOI Scopus8 WoS5 Europe PMC4
- Joshi, R., Hocking, C., O’Neill, S., Singhal, N., Kee, M., & Keefe, D. M. (2022). A Prospective Audit of Inpatient Medical Oncology Consultation Patterns in a Tertiary Teaching Hospital in South Australia. Global Journal Of Epidemiology and Public Health, 1(2), 42-47.
DOI

Year Citation
2025 Gusain, S., Patial, A., Chandoliya, R., Sharma, V., & Joshi, R. (2025). Metabolomics and High-throughput Approaches to Assessing Drought-stress Tolerance in Crops. In J. T. Chen (Ed.), HIGH-THROUGHPUT PLANT METABOLOMICS (pp. 201-215). CABI PUBLISHING-C A B INT.
DOI WoS1
2025 Patial, A., Chandoliya, R., Gusain, S., Sharma, V., & Joshi, R. (2025). Insights into Medicinal Herbs Based on Metabolomics and High-throughput Technologies. In J. T. Chen (Ed.), HIGH-THROUGHPUT PLANT METABOLOMICS (pp. 350-370). CABI PUBLISHING-C A B INT.
DOI
2018 Joshi, R., & Hong, H. W. (2018). Ascites. In Mascc Textbook of Cancer Supportive Care and Survivorship (pp. 437-443). Springer International Publishing.
DOI
2011 Joshi, R. (2011). Ascites. In I. N. Olver (Ed.), MASCC TEXTBOOK OF CANCER SUPPORTIVE CARE AND SURVIVORSHIP (pp. 261-265). SPRINGER-VERLAG BERLIN.
DOI

Year Citation
2025 Nguyen, C., Chew, G., & Joshi, R. (2025). EFFECT OF LETROZOLE IN FDG PET FOR BONY METASTASIS FROM BREAST CARCINOMA. In INTERNAL MEDICINE JOURNAL Vol. 55 (pp. 25-26). WILEY.
2025 Arefin, F., Forgioine, M., Maxter, T., Tallboy, T., Lamb, A., Cahyadi, N., . . . Kwatra, V. (2025). Evaluation of the Non-Small Cell Lung Cancer Referral Pathway at Northern Adelaide Local Health Network (NALHN), a Single Hospital Experience. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 21 (pp. 1 page). WILEY.
2025 Joshi, S., & Joshi, R. (2025). Surviving and Thriving: Sensing and Signaling Mechanism in Alpine Himalayan Medicinal Plant<i> Nardostachys</i><i> jata</i><i>mansi</i>. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER.
2025 Kumari, L. K., & Joshi, R. (2025). Integrating Artificial Intelligence and Multi-omics for Precision Organogenesis, Embryogenesis and Secondary Metabolite Production in<i> Ferula</i><i> assa-foetida.</i>. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER.
2025 Gusain, S., & Joshi, R. (2025). Molecular Dynamics Underlying Elicitor-induced Fortification to Drought Stress Reveal Crosstalk Between Calcium Ions and Nitric Oxide Signaling. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER.
2025 Joshi, R., Zardavas, D., Ragone, A., Chica-Duque, S., Wang, Y., Liu, Y., . . . Van Tine, B. A. (2025). A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2-breast cancer and other advanced solid tumors: First disclosure of clinical data.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 3115). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS2
2025 Heist, R., Shum, E., Garcia, E., Itchins, M., Gao, B., Han, J. -Y., . . . Kim, H. R. (2025). MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 8613). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS4
2024 Kumari, A., & Joshi, R. (2024). Revolutionizing Cultivation of Economic Bamboo Species: Macro-Propagation, Micro-Propagation and Nano-Elicitation Approaches. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 60 (pp. S115-S116). SPRINGER.
2024 Joshi, S., & Joshi, R. (2024). Multifaceted Approach to Understand the Survival Mechanism of High Altitude, Perennial and Endangered Medicinal Plant <i>Nardostachys jatamansi</i>.. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 60 (pp. S138). SPRINGER.
2024 Lim, A., Zobel, J., Bills, M., Hsieh, W., Crouch, B., Joshi, R., . . . Nguyen, N. (2024). Impact of intra-tumoral injection of Phosphorus-32 microparticles on vascularity in locally advanced pancreatic carcinoma. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 39 (pp. 235). WILEY.
2024 Price, T. J., Joshi, R., Karapetis, C. S., Cooper, P., Hocking, C., Singhal, N., & Townsend, A. R. (2024). Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2024 Penumarty, R. D., Forgione, M., Patel, D., Hocking, C., Joshi, R., & Kwatra, V. (2024). The use of durvalumab following definitive chemo-radiotherapy in unresectable stage III non-small-cell lung cancer - An experience of the Northern Adelaide Cancer Centre. In Abstracts from the COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities as published in Asia-Pacific Journal of Clinical Oncology Vol. 20 (pp. 256-136-256-137). United Kingdom: Wiley.
DOI
2023 Jankowski, T., Soter, S., Raumlau, R., Chilingirova, N., Cholakova, M. D., Seidl, B., . . . Obrocea, M. (2023). A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results. In ANNALS OF ONCOLOGY Vol. 34 (pp. 1 page). SPAIN, Madrid: ELSEVIER.
DOI
2022 Ly, Y. J., Hocking, C., Joshi, R., Patel, D., Hong, H., McGregor, M., . . . Kwatra, V. (2022). Real-world comparative data on addition of Atezolizumab to platinum-doublet chemotherapy in extensive stage small cell lung cancer - A single South Australian institution experience. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 163-164). WILEY.
2022 Ciuleanu, T. -E., Joshi, R., Gryaznov, S., Vitoc, V., & Obrocea, M. (2022). A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC. In ANNALS OF ONCOLOGY Vol. 33 (pp. S1094). ELECTR NETWORK: ELSEVIER.
DOI WoS1
2022 Joshi, R., Goh, J., Joubert, W., Kwarta, V., Okera, M., Bishnoi, S., . . . Gargosky, S. (2022). CLINICAL UPDATE FROM A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL SINGLE AGENT STUDY OF SUPLEXA THERAPEUTIC CELLS IN PATIENTS WITH METASTATIC SOLID TUMOURS AND HAEMATOLOGIC MALIGNANCIES. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 10 (pp. A663). BMJ PUBLISHING GROUP.
DOI
2022 Hays, J., Li, T., Chen, H., Zahrah, G., Frank, R., Hamm, J., . . . O'Malley, D. (2022). SAFETY AND CLINICAL ACTIVITIES OF THE ACID PH-SENSITIVE ANTI-CTLA-4 MAB ONC-392 IN OVARIAN CANCER PATIENTS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 10 (pp. A591). BMJ PUBLISHING GROUP.
DOI
2020 Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., . . . Joshi, R. (2020). Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141). In CANCER RESEARCH Vol. 80 (pp. 3 pages). TX, San Antonio: AMER ASSOC CANCER RESEARCH.
DOI WoS10
2020 Chan, M. M., Hocking, C., Joshi, R., Patel, D., Singhal, N., McGregor, M., . . . Kwatra, V. (2020). A shift towards virtual multidisciplinary tumour board meeting during COVID 19 pandemic - A South Australian Survey. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 167). WILEY.
2020 Solanki, R., & Joshi, R. (2020). Outcomes in lung cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 177-178). WILEY.
2017 Townsend, A. R., Hardingham, J., Tebbutt, N. C., Karapetis, C. S., Singhal, N., Joshi, R., . . . Price, T. J. (2017). A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS1
2016 Burdett, N., Hong, H., Roberts, S., Adams, J., Hocking, C., & Joshi, R. (2016). AVOIDING THE EMERGENCY DEPARTMENT: A RAPID ASSESSMENT AND SUPPORTIVE CARE CLINIC IN A BUSY AUSTRALIAN CANCER CENTER. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 12 (pp. 150). WILEY-BLACKWELL.
WoS1
2015 Patel, D., Abdghan, N., Kerr, K. -A., Row, J., Adams, J., & Joshi, R. (2015). Clinical presentation and management pattern of venous thrombosis in patients receiving chemotherapy. In ANNALS OF ONCOLOGY Vol. 26 (pp. 116-117). Singapore, SINGAPORE: OXFORD UNIV PRESS.
2007 Joshi, R., O'Neill, S., & Keefe, D. (2007). A prospective audit of inpatient medical oncology consultation patterns in a tertiary teaching hospital in South Australia. In ANNALS OF ONCOLOGY Vol. 18 (pp. 196-197). Lugano, SWITZERLAND: OXFORD UNIV PRESS.

Year Citation
2026 Patnaik, A., Sharma, M. R., McKean, W. B., Joshi, R., Giordano, A., Tang, S. -C., . . . Patel, M. R. (2026). A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2-advanced breast cancer (ABC): Preliminary results. Poster session presented at the meeting of Abstracts from the ASCO Annual Meeting as published in Journal of Clinical Oncology. United States: American Society of Clinical Oncology.
DOI
2026 Fu, S., Pinato, D. J., Khattak, M. A., Joshi, R., Oing, C., Childs, A., . . . Long, G. V. (2026). BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors. Poster session presented at the meeting of Abstracts from the ASCO 2026 Annual Meeting as published in Journal of Clinical Oncology. United States: American Society of Clinical Oncology.
DOI
2026 Yan, F., Mukohara, T., Park, Y., Im, S., Kim, G., Yamashita, T., . . . Lorusso, P. (2026). A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER +/HER2# locally advanced or metastatic breast cancer. Poster session presented at the meeting of Abstracts of the San Antonio Breast Cancer Symposium as published in Clinical Cancer Research. United States: American Association for Cancer Research.
DOI
2025 Lemech, C., Humphries, T., Biachi de Castria, T., Cercek, A., Overman, M., Kummar, S., . . . Ballas, M. (2025). Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design. Poster session presented at the meeting of Abstracts from the International Conference on Molecular Targets and Cancer Therapeutics as published in Molecular Cancer Therapeutics. United States: American Association for Cancer Research.
DOI WoS1
2024 Lim, A., Zobel, J., Bills, M., Hsieh, W., Crouch, B., Joshi, R., . . . Nguyen, N. (2024). Impact of intra-tumoral injection of Phosphorus-32 microparticles on vascularity in locally advanced pancreatic carcinoma. Poster session presented at the meeting of Abstracts of the Asian Pacific Digestive Week as published in Journal of Gastroenterology and Hepatology (Australia). Australia: Wiley.
DOI
2024 Pulford, J. F., Lederer, J. A., Murzin, E., Younger, D., Goh, J. C., Kitchenadasse, G., . . . Joshi, R. (2024). Effect of novel autologous immune training platform on end-stage patients with cancer. Poster session presented at the meeting of Abstracts from the ASCO Annual Meeting Special Clinical Science Symposia as published in Journal of Clinical Oncology. United States: LIPPINCOTT WILLIAMS & WILKINS.
DOI
2024 Jankowski, T., Csoszi, T., Urban, L., Nagy, T., Chilingirova, N., Cholakova, M., . . . Zaporojan, V. (2024). A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results. Poster session presented at the meeting of Abstracts of the ASCO Annual Meeting Special Clinical Science Symposia as published in Journal of Clinical Oncology. United States: American Society of Clinical Oncology.
DOI WoS1
2024 Lenz, H. J., Lonardi, S., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., . . . Andre, T. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.. Poster session presented at the meeting of Abstracts from the ASCO Annual Meeting as published in Journal of Clinical Oncology. United States: American Society of Clinical Oncology.
DOI Scopus19 WoS12
2024 Lonardi, S., Andre, T., Arnold, D., Garcia-Carbonero, R., Chalabi, M., Elez Fernandez, M. E., . . . Van Cutsem, E. (2024). Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW. Poster session presented at the meeting of Abstracts from the Gastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology as published in Annals of Oncology. Netherlands: Elsevier.
DOI WoS2
2024 Lim, A. H., Nitchingham, D., Bednarz, J., Bills, M., Lanka, L., Allen, B., . . . Nguyen, N. (2024). Combined phosphorus-32 implantation and chemotherapy: a comparison with standard therapy using a propensity-score weighted landmark analysis and an assessment of its impact on vascularity in locally advanced pancreatic cancer. Poster session presented at the meeting of Abstracts from the Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) as published in Journal Of Gastroenterology And Hepatology. Australia: WILEY.
DOI
2024 Forgione, M., Penumarty, R., Joshi, R., Patel, D., Hocking, C., & Kwatra, V. (2024). Lack of TTF-1 Expression Predicts Poor Outcomes in Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with First-Line Pembrolizumab-Containing Regimens. Poster session presented at the meeting of Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting as published in Asia-Pacific Journal of Clinical Oncology. United Kingdom: Wiley.
DOI
2023 Lim, A. H. W., Weilert, F., Singhal, N., Allen, B., Bartholomeusz, D., Lanka, L., . . . Nguyen, N. Q. (2023). Combined chemotherapy and phosphorus-32 microparticle intratumoral implantation in patients with locally advanced pancreatic adenocarcinoma: Australian and New Zealand experience. Poster session presented at the meeting of Abstracts from the Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) as published in Journal of Gastroenterology and Hepatology. Australia: WILEY.
DOI
2023 Rainey, N., Joshi, R., Chiu, J., Chen, A., Wang, H., Odegard, J., . . . Adams, S. (2023). A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC. Poster session presented at the meeting of Abstracts of the Annual Meeting of the American-Society of Clinical Oncology (ASCO23), as published in Journal of Clinical Oncology. Chicago, IL: American Society of Clinical Oncology (ASCO).
DOI WoS2
2023 Rainey, N., Joshi, R., Chiu, J. W. Y., Chen, A., Wang, H., Odegard, J., . . . Adams, S. (2023). Abstract OT2-10-01: A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer. Poster session presented at the meeting of Abstracts from the San Antonio Breast Cancer Symposium as published in Cancer Research. United States: American Association for Cancer Research (AACR).
DOI WoS1
2023 He, K., Carbone, D. P., McKean, M., Balaraman, R., Shah, S., Arrowsmith, E., . . . Li, T. (2023). Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.. Poster session presented at the meeting of Abstracts of the Annual Meeting of the American-Society of Clinical Oncology (ASCO23), as published in Journal of Clinical Oncology. Chicago, IL: American Society of Clinical Oncology (ASCO).
DOI WoS3
2023 Obrocea, M., Seidl, B., Joshi, R., Moore, M., Vitoc, V., Yao, B., & Gryaznov, S. (2023). Abstract CT050: A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC. Poster session presented at the meeting of Abstracts from the AACR Annual Meeting as published in Cancer Research. United States: American Association for Cancer Research (AACR).
DOI
2022 Johnson, M. L., Fox, W., Lee, Y. -G., Lee, K. H., Ahn, H. K., Kim, Y. -C., . . . Joshi, R. (2022). ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC). Poster session presented at the meeting of Abstracts from the ASCO Monthly Plenary Series as published in ournal of Clinical Oncology. United States: American Society of Clinical Oncology (ASCO).
DOI
2022 Telli, M., Devitt, B., Cuff, K., Vinayak, S., Nanda, R., Montero, A. J., . . . Joshi, R. (2022). Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141). Poster session presented at the meeting of Proceedings of the 2021 San Antonio Breast Cancer Symposium as published in Cancer Research. United States: American Association for Cancer Research (AACR).
DOI WoS2
2022 Cilento, M. A., Chalwin, R., Hocking, C., Chan, L., Smithers, L., & Joshi, R. (2022). Morbidity and mortality of oncology patients admitted to an intensive care unit. Poster session presented at the meeting of Abstracts from the RACP Congress 2022 A Climate for Change as published in Internal Medicine Journal. Australia: John Wiley & Sons.
DOI
2019 Fernandez-Penas, P., Carlino, M., Atkinson, V., Telli, M., Joshi, R., Thomas, S., . . . Algazi, A. (2019). Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis. Poster session presented at the meeting of JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
2018 Telli, M., Wapnir, I., Vinayak, S., Soliman, H., Cuff, K., Devitt, B., . . . Joshi, R. (2018). A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple-negative breast cancer. Poster session presented at the meeting of San Antonio Breast Cancer Symposium. San Antonio, Texas.
2016 Doherty, T., Hislop, C., Fitzgerald, M., Campbell, J., Poprawski, D., Roberts, S., . . . Koczwara, B. (2016). CONTEXT IMPACTS OUTCOMES: LESSONS LEARNT FROM THE SOUTH AUSTRALIAN SURVIVORSHIP FRAMEWORK PILOT IMPLEMENTATION. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2016 Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. J. (2016). A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI Scopus1 WoS1
2016 Joshi, R., Connolly, P., Foo, T., & Rowe, J. (2016). Hypomagnesaemia in the context of cetuximab/panitumumab and proton pump inhibitor therapy. Poster session presented at the meeting of ANNALS OF ONCOLOGY. OXFORD UNIV PRESS.
2013 Vatandoust, S., Joshi, R., Pittman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2013). A descriptive study of persistent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer. Poster session presented at the meeting of Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Blood, Biomarkers and Beyond, 31 July - 2 August 2013, as published in Asia-Pacific Journal of Clinical Oncology. Melbourne, Victoria: Wiley-Blackwell.
DOI
2013 Townsend, A. R., Pirc, L., Cooper, P., Tebbutt, N. C., Karapetis, C. S., Singhal, N., & Price, T. J. (2013). A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS2
2012 Grover, S., Depasquale, C., Leong, D., Cheong, K., Kotasek, D., Joshi, R., . . . Selvanayagam, J. (2012). Biventricular dysfunction following administration of anthracycline based chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers. Poster session presented at the meeting of EUROPEAN HEART JOURNAL. Munchen, GERMANY: OXFORD UNIV PRESS.
2012 Vatandoust, S., Joshi, R., Broadbridge, V., Pittman, K. B., Adams, J., Singhal, N., . . . Price, T. J. (2012). Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2011 Cheng, H. B., To, T., Joshi, R., & Singhal, N. (2011). OUTCOMES OF GERIATRIC ASSESSMENT FOR OLDER LUNG CANCER PATIENTS FROM A DEDICATED GERIATRIC ONCOLOGY PROGRAM. Poster session presented at the meeting of JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
WoS2

Connect With Me

External Profiles

Other Links